Evidence map›Paper›PMID 37965230›Full record

ReviewERJ open research2023

Pulmonary hypertension associated with diazoxide: the SUR1 paradox.

David Montani, Fabrice Antigny, Etienne-Marie Jutant, Marie-Camille Chaumais, Hélène Le Ribeuz, Julien Grynblat, Charles Khouri, Marc Humbert

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

David MontaniUniversité Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-9358-6922
Fabrice AntignyUniversité Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-9515-6571
Etienne-Marie JutantCHU de Poitiers, Respiratory Department, INSERM CIC 1402, IS-ALIVE Research Group, University of Poitiers, Poitiers, France.ORCID https://orcid.org/0000-0002-1374-1890
Marie-Camille ChaumaisINSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France.ORCID https://orcid.org/0000-0002-1217-8442
Hélène Le RibeuzUniversité Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0002-6579-6076
Julien GrynblatUniversité Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0001-5593-3383
Charles KhouriUniv. Grenoble Alpes, HP2 Laboratory, Grenoble, France.ORCID https://orcid.org/0000-0002-8427-8573
Marc HumbertUniversité Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.ORCID https://orcid.org/0000-0003-0703-2892
Inserm · FRUniversité Grenoble Alpes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ATP-sensitive potassium channels and their regulatory subunits, sulfonylurea receptor 1 (SUR1/Kir6.2) and SUR2/Kir6.1, contribute to the pathophysiology of pulmonary hypertension (PH). Loss-of-function pathogenic variants in the

Identifiers

PMID37965230
PMCPMC10641583
OpenAlexW4387569721

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.